Evotec
link all discovery and development work to patients | Evotec
Company
Deck Type
Sector
Industry
Deck date
November 2020
Slide
83 of 103
Related slides by other companies
Alkermes
Investor Day
March 2021
development plan seek early clinical evidence of activity synaptic and assessments are core components of the early clinical development plan and program decision making early clinical development plan objectives phase study planned initiation phase sad mad planned initiation identify differences in synaptic between healthy volunteers and patients with neurodegenerative diseases and inform indication selection determine relationship and in healthy volunteers determine effects on select phase basket studies in and neurodegenerative disorders confirm effect on of and function indications and for proof of concept studies sad single ascending dose mad multiple ascending dose pharmacodynamic maximum tolerated dose | Alkermes
OmniAb
Investor Presentation
May 2023
growth of partner programs | OmniAb
23andMe
Investor Presentation
April 2023
the program is a prime example of the value brings to drug discovery and development | 23andMe
BenevolentAI
Investor Presentation
June 2022
leveraging to increase efficiency of the drug discovery process | BenevolentAI
Other recent decks by Evotec
See all presentations (5 decks)
Investor Presentation
March 2024
Investor Presentation
July 2022
ESG
February 2022
Results
August 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io